iProteos is a R&D pharma company, a spin-off from the Institute for Research in Biomedicine (IRB, Barcelona, Spain) and the Universitat de Barcelona (UB, Spain), developing new medicines to treat brain disorders with a high social and economic impact worldwide. The company has benefited from a Series A financing led by Caixa Capital Risk and Kinled.

iProteos demonstrated the effectiveness of 2 compounds in animal models:

IPR-166 (propyl oligopeptidase inhibitor) to reverse the cognitive deficit associated with certain brain disorders

IPR-179 (gelatinase inhibitor) to act directly on epileptogenesis, thus preventing the appearance of seizures in patients suffering from epilepsy

Since May 26, 2020, the two programs, IPT-166 and IPR-179, have been integrated into the portfolio of Accure Therapeutic under the names ACT-02 and ACT-03 respectively.